IMUN Immune Therapeutics Inc (PK)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2023

 

 

BIOSTAX CORP

(Exact name of registrant as specified in its charter)

 

 

Florida		000-54933		59-3226705
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation)		File Number)		Identification No.)

 

2431 Aloma Ave, Suite 124, Winter Park, FL 32792

(Address of Principal Executive Offices) (Zip Code)

 

888-391-9355

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common		BTAX		OTC Pink

 

 

 

SECTION 5 — CORPORATE GOVERNANCE AND MANAGEMENT

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   Appointment of Clay Caperton Renyolds as Director   On October 24, 2023 the board of directors of Biostax Corp, (the “Company”) appointed Ms. Mary Clay Caperton, age 61 to the Board of Directors in accordance with the bylaws of the Issuer.   Ms. Caperton began her career in the Sports Management Industry and then expanded to working with not-for-profit organizations. She was a member of the Steward School Board of Trustees from 2016-2022 and that included her membership on the Advancement, Governance and Executive Committees. Since 2019, she has been a member of the Bon Secours Richmond Foundation Board and its Development Committee; since 2022 she has also been a member of the Riverside School Board of Trustees, where she is the vice chair of the Development & Governance Committees; since 2022 she has been a member of the Trinity Episcopal School Board of Trustees and is the Chair of its Advancement Committee. Ms. Caperton went to Virginia Polytechnic Institute & State University from 1980-1983 and attended Virginia Commonwealth University from 1984-1986 where she earned a B.S. in Sociology & Anthropology.   There are no arrangements or understandings between Ms. Caperton and any other persons pursuant to which she was selected as a director. There are no family relationships that exist between Ms. Caperton and any directors or executive officers of the Company. In addition, there has been no transaction, nor is there any currently proposed transaction between Ms. Caperton and the Company that would require disclosure under Item 404(a) of Regulation S-K.

 

SECTION 8 — OTHER EVENTS

 

Item 8.01

Other Events.   On November 2, 2023 Biostax Corp (the “Company”) issued a press release announcing the appointment of Ms. Mary Clay Caperton to its Board of Directors. A Copy of the press release is attached to this report as Exhibit 99.1. The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

 

SECTION 9 — FINANCIAL STATEMENTS AND EXHIBITS

 

Item 9.01	Financial Statements and Exhibits.
	(d) Exhibits.

 

Exhibit No.		Description of Exhibit
99.1		Press Release Dated November 2, 2023
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

	BISOSTAX CORP
	By	/s/ Noreen Griffin
	Name:	Noreen Griffin
	Title:	Chief Executive Officer

 

Date: November 2, 2023

 

 

INDEX TO EXHIBITS

 

Exhibit No.		Description
99.1		Press Release Dated November 2, 2023
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

 

 

Exhibit 99.1

 

Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors

 

Orlando, FL, November. 2, 2023 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC, boasting a rich history in the dynamic realm of sports management and has maintained a fervent dedication to the not-for-profit sector spanning over two decades. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys & Girls Clubs of Richmond, St. Mary’s Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond.

 

In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a fundraising professional, showcasing an unwavering passion for aiding not-for-profit organizations in realizing their missions. With an impressive track record, she has adeptly secured substantial financial contributions and cultivated robust donor networks. She has taken on pivotal roles, serving on and chairing various committees such as the Organization’s Development or Advancement Committee, the Capital Campaign Committee, and the Governance and Executive Committee. Her expertise has shined through as she has successfully assumed the role of Tournament Director for numerous Charity Golf Events, Banquets, and Auctions.

 

Early in her career, Ms. Caperton served as the Assistant Marketing Manager for the Richmond Braves, the AAA Franchise of the Atlanta Braves. Subsequently, at Sports Development League (SDL), a player agency representing professional baseball and football players in the US, she honed her resourcefulness, flexibility, and adeptness in dealing with diverse personalities. These invaluable skills laid the foundation for her future roles in event management.

 

Mrs. Caperton’s impact extended to the academic sphere as well. Collaborating with Virginia Commonwealth University, she played a pivotal role in the development of a Sports Marketing Graduate Program, overseeing internships, and contributing to the formulation of event management and operations curricula.

 

Furthermore, her outstanding reputation led to her appointment as the Director of the Henrico County Open on the Nationwide Tour by The PGA Tour. Over six years, she adeptly managed this televised event, showcasing her unwavering dedication to excellence and organizational prowess.

 

Noreen Griffin, CEO of Biostax, stated “I warmly welcome Ms. Caperton to our esteemed Board of Directors. We are thrilled to have her on board, as her wealth of experience and unwavering dedication to excellence align perfectly with our company’s vision and values. With her arrival, we anticipate not only the enhancement of our fundraising initiatives but also the fostering of valuable relationships with key organizations, paving the way for unprecedented growth and impact.”

 

 

Mrs. Caperton’s multifaceted career stands as a testament to her unwavering commitment to excellence, innovation, and impactful contributions to both the sports and not-for-profit sectors.

 

About Biostax

 

Biostax is an innovative biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology (MedTech) products with a well -defined path to market. We use a hub-and-spoke business model, where the parent company (hub) holds a centralized management and administrative team, and each subsidiary (spoke) operates a specialized development team focused on individual product pipelines.

 

Where Biostax has a diversity of product pipelines that will provide revenue while reducing risk, our goal is to develop new therapies that provide disease remission by restoring immune balance for patients with autoimmune, inflammatory, and infectious diseases without suppressing their immune system. Restoring homeostasis or balance to the immune system is the first step to a cure by improving patients’ lives in chronic illness caused by immune dysfunction and inflammation. www.biostaxcorp.com

 

Forward Looking Statement

 

This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions, and expectations of Immune’s future economic performance, considering the information currently available to it. These statements are not statements of historical fact. Although Immune believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Immune does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Immune will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause Immune’s actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory review and approval of our prospective products, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

 

Disclaimer

 

The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure, or prevent any disease.

 

v3.23.3

Cover	Oct. 24, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 24, 2023
Entity File Number	000-54933
Entity Registrant Name	BIOSTAX CORP
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	391-9355
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common
Trading Symbol	BTAX

---